Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

NCT02903537 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Chronic Progressive

Interventions

DRUG: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
DRUG: Interferon-beta

Sponsor

Fundació Institut Germans Trias i Pujol

Collaborators

[object Object]